Clinical trial
A Randomized, Double Blind, Placebo and Active Controlled Parallel Group Study to Evaluate the Efficacy and Safety of Risperidone Long-acting Injectable (LAI) for the Prevention of Mood Episodes in the Treatment of Subjects With Bipolar I Disorder
NCT00391222 is registered in ClinicalTrials.gov with Janssen Pharmaceutica N.V., Belgium as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Randomized, Double Blind, Placebo and Active Controlled Parallel Group Study to Evaluate the Efficacy and Safety of Risperidone Long-acting Injectable (LAI) for the Prevention of Mood Episodes in the Treatment of Subjects With Bipolar I Disorder
- Lead sponsor
- Janssen Pharmaceutica N.V., Belgium
- Phase
- Phase 3
- Overall status
- Completed
- Start date
- November 30, 2006
- Completion date
- April 30, 2009
- Enrollment
- 585 (actual)
- Sites
- 63
Conditions
As the registry lists them; a condition with its own page is linked.